110 related articles for article (PubMed ID: 22546877)
21. PET/CT using ¹⁸F-FDOPA provides improved staging of carcinoid tumor patients in a Canadian setting.
Yakemchuk VN; Jager PL; Chirakal R; Reid R; Major P; Gulenchyn KY
Nucl Med Commun; 2012 Mar; 33(3):322-30. PubMed ID: 22183015
[TBL] [Abstract][Full Text] [Related]
22. Role of [(18)F]FDG-PET/CT in the detection of occult recurrent medullary thyroid cancer.
Skoura E; Rondogianni P; Alevizaki M; Tzanela M; Tsagarakis S; Piaditis G; Tolis G; Datseris IE
Nucl Med Commun; 2010 Jun; 31(6):567-75. PubMed ID: 20335822
[TBL] [Abstract][Full Text] [Related]
23. Fluorine-18 fluorodeoxyglucose positron emission tomography in medullary thyroid cancer: results of a multicentre study.
Diehl M; Risse JH; Brandt-Mainz K; Dietlein M; Bohuslavizki KH; Matheja P; Lange H; Bredow J; Körber C; Grünwald F
Eur J Nucl Med; 2001 Nov; 28(11):1671-6. PubMed ID: 11702109
[TBL] [Abstract][Full Text] [Related]
24. The clinical value of [18F]fluoro-dihydroxyphenylalanine positron emission tomography in primary diagnosis, staging, and restaging of neuroendocrine tumors.
Kauhanen S; Seppänen M; Ovaska J; Minn H; Bergman J; Korsoff P; Salmela P; Saltevo J; Sane T; Välimäki M; Nuutila P
Endocr Relat Cancer; 2009 Mar; 16(1):255-65. PubMed ID: 19088184
[TBL] [Abstract][Full Text] [Related]
25. [18F]fluoromethylcholine (FCH) positron emission tomography/computed tomography (PET/CT) for lymph node staging of prostate cancer: a prospective study of 210 patients.
Poulsen MH; Bouchelouche K; Høilund-Carlsen PF; Petersen H; Gerke O; Steffansen SI; Marcussen N; Svolgaard N; Vach W; Geertsen U; Walter S
BJU Int; 2012 Dec; 110(11):1666-71. PubMed ID: 22520686
[TBL] [Abstract][Full Text] [Related]
26. The additive clinical value of 18F-FDG PET/CT in defining the recurrence of disease in patients with differentiated thyroid cancer who have isolated increased antithyroglobulin antibody levels.
Ozkan E; Soydal C; Araz M; Aras G; Ibis E
Clin Nucl Med; 2012 Aug; 37(8):755-8. PubMed ID: 22785502
[TBL] [Abstract][Full Text] [Related]
27. Can (18)F-FDOPA PET/CT predict survival in patients with suspected recurrent glioma? A prospective study.
Karunanithi S; Sharma P; Kumar A; Gupta DK; Khangembam BC; Ballal S; Kumar R; Kumar R; Bal C
Eur J Radiol; 2014 Jan; 83(1):219-25. PubMed ID: 24191944
[TBL] [Abstract][Full Text] [Related]
28. Early acquisition of [
Kjærulff MLG; Dias AH; Iversen P; Gormsen LC; Hjorthaug K
Eur J Hybrid Imaging; 2022 Aug; 6(1):20. PubMed ID: 36002696
[TBL] [Abstract][Full Text] [Related]
29. Diagnostic accuracy and prognostic value of 18F-FDG PET in Hürthle cell thyroid cancer patients.
Pryma DA; Schöder H; Gönen M; Robbins RJ; Larson SM; Yeung HW
J Nucl Med; 2006 Aug; 47(8):1260-6. PubMed ID: 16883003
[TBL] [Abstract][Full Text] [Related]
30. 18F-FDOPA PET and PET/CT accurately localize pheochromocytomas.
Imani F; Agopian VG; Auerbach MS; Walter MA; Imani F; Benz MR; Dumont RA; Lai CK; Czernin JG; Yeh MW
J Nucl Med; 2009 Apr; 50(4):513-9. PubMed ID: 19289420
[TBL] [Abstract][Full Text] [Related]
31. Comparison of ⁶⁸Ga-DOTATATE PET-CT, ¹⁸F-FDG PET-CT and 99mTc-(V)DMSA scintigraphy in the detection of recurrent or metastatic medullary thyroid carcinoma.
Ozkan ZG; Kuyumcu S; Uzum AK; Gecer MF; Ozel S; Aral F; Adalet I
Nucl Med Commun; 2015 Mar; 36(3):242-50. PubMed ID: 25369749
[TBL] [Abstract][Full Text] [Related]
32. Utility of (18)F-FDG PET-CT in staging and restaging of patients with malignant salivary gland tumours: a single-institutional experience.
Sharma P; Jain TK; Singh H; Suman SK; Faizi NA; Kumar R; Bal C; Malhotra A; Kumar R
Nucl Med Commun; 2013 Mar; 34(3):211-9. PubMed ID: 23353886
[TBL] [Abstract][Full Text] [Related]
33. Diagnosis of metastases from postoperative differentiated thyroid cancer: comparison between FDG and FLT PET/CT studies.
Nakajo M; Nakajo M; Jinguji M; Tani A; Kajiya Y; Tanabe H; Fukukura Y; Nakabeppu Y; Koriyama C
Radiology; 2013 Jun; 267(3):891-901. PubMed ID: 23468571
[TBL] [Abstract][Full Text] [Related]
34. (18)F-DOPA PET/CT and MRI: description of 12 histologically-verified pheochromocytomas.
Magnaldi S; Mayerhoefer ME; Khameneh A; Schuetz M; Javor D; Mitterhauser M; Dudczak R; Hacker M; Karanikas G
Anticancer Res; 2014 Feb; 34(2):791-5. PubMed ID: 24511014
[TBL] [Abstract][Full Text] [Related]
35. Diagnostic accuracy of dual-time-point 18F-FDG PET/CT for the detection of axillary lymph node metastases in breast cancer patients.
Hahn S; Hecktor J; Grabellus F; Hartung V; Pöppel T; Kimmig R; Forsting M; Antoch G; Heusner TA
Acta Radiol; 2012 Jun; 53(5):518-23. PubMed ID: 22547387
[TBL] [Abstract][Full Text] [Related]
36. Relationship between positive thyroglobulin doubling time and 18F-FDG PET/CT-positive, 131I-negative lesions.
Kelders A; Kennes LN; Krohn T; Behrendt FF; Mottaghy FM; Verburg FA
Nucl Med Commun; 2014 Feb; 35(2):176-81. PubMed ID: 24201550
[TBL] [Abstract][Full Text] [Related]
37. Clinical relevance of 18F-FDG PET and 18F-DOPA PET in recurrent medullary thyroid carcinoma.
Verbeek HH; Plukker JT; Koopmans KP; de Groot JW; Hofstra RM; Muller Kobold AC; van der Horst-Schrivers AN; Brouwers AH; Links TP
J Nucl Med; 2012 Dec; 53(12):1863-71. PubMed ID: 23081996
[TBL] [Abstract][Full Text] [Related]
38. Technetium-99m-sestamibi scanning in recurrent medullary thyroid carcinoma.
Learoyd DL; Roach PJ; Briggs GM; Delbridge LW; Wilmshurst EG; Robinson BG
J Nucl Med; 1997 Feb; 38(2):227-30. PubMed ID: 9025742
[TBL] [Abstract][Full Text] [Related]
39. [Evaluation of efficacy and clinical impact of 18F-FDG-PET in the diagnosis of recurrent medullary thyroid cancer with increased calcitonin and negative imaging test].
Gómez-Camarero P; Ortiz-de Tena A; Borrego-Dorado I; Vázquez-Albertino RJ; Navarro-González E; Ruiz-Franco-Baux JV; Cuenca-Cuenca JI
Rev Esp Med Nucl Imagen Mol; 2012 Sep; 31(5):261-6. PubMed ID: 23067528
[TBL] [Abstract][Full Text] [Related]
40. 18F-dihydroxyphenylalanine PET in patients with biochemical evidence of medullary thyroid cancer: relation to tumor differentiation.
Koopmans KP; de Groot JW; Plukker JT; de Vries EG; Kema IP; Sluiter WJ; Jager PL; Links TP
J Nucl Med; 2008 Apr; 49(4):524-31. PubMed ID: 18375923
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]